Shares of Celsion CLSN rose 2% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 37.93% year over year to ($0.18), which missed the estimate of ($0.14).
Revenue of $125,000 unchanged by 0.00% year over year, which beat the estimate of $80,000.
Outlook
Celsion hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Aug 14, 2020
Time: 11:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/umwnv2dw
Recent Stock Performance
52-week high: $6.50
Company's 52-week low was at $0.69
Price action over last quarter: down 21.99%
Company Description
Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
